Novo Nordisk shares fall after deal with Trump to slash obesity drug prices

Core Viewpoint - Shares in Novo Nordisk declined following a deal between Eli Lilly and U.S. President Donald Trump to reduce prices of GLP-1 weight-loss medications [1] Company Summary - Novo Nordisk's stock experienced a drop at market opening on Friday due to competitive pricing pressures from a new agreement involving Eli Lilly [1] - The agreement aims to lower the costs of GLP-1 weight-loss drugs, which could impact Novo Nordisk's market position and sales [1] Industry Summary - The deal between Eli Lilly and the U.S. government signifies a shift in the pharmaceutical industry towards more aggressive pricing strategies for weight-loss medications [1] - This development may lead to increased competition in the GLP-1 drug market, affecting pricing and accessibility for consumers [1]